(Q44256443)

1 December 2017

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany (English)

1 reference

cost-effectiveness analysis

1 December 2017

0 references

0 references

1 reference

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

1 reference

Arthi Vijayaraghavan

1

1 reference

1 December 2017

Molly B Efrusy

2

1 reference

1 December 2017

Burkhard Göke

3

1 reference

1 December 2017

Thomas Kirchner

4

1 reference

1 December 2017

Christopher C Santas

5

1 reference

1 December 2017

Richard M Goldberg

6

1 reference

1 December 2017

language of work or name

English

0 references

publication date

3 January 2012

1 reference

International Journal of Cancer

1 December 2017

1 reference

1 December 2017

131

1 reference

1 December 2017

2

1 reference

1 December 2017

438-445

1 reference

NCCN Clinical Practice Guidelines in Oncology: colon cancer

1 December 2017

1 reference

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis

21 January 2018

1 reference

A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer.

21 January 2018

1 reference

Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment

21 January 2018

1 reference

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue

21 January 2018

1 reference

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

21 January 2018

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.26400

1 reference

1 December 2017

1 reference